



About the Biotechnology Innovation Organization (BIO)

BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world's largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients' lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org.

BIO Centers of Excellence



Health Policy and Programs

Empowering innovation, advocacy, and access; dedicated focus areas on access and reimbursement, infectious disease and vaccines.



Emerging Companies and Economic Growth

Fostering capital formation and policies that help companies grow, advance science, and ultimately develop new products.



Science & Regulatory Affairs

Focused on modernizing agency regulatory processes so that cuttingedge science and technology can prosper.



Communications

Committed to outstanding storytelling, supporting policy and advocacy through communication, and executing a strategy that conveys biotechnology's critical importance.



Federal Government Affairs

Leading advocacy efforts with the federal government to advance policies that enable science and improve lives.



National Security and International Affairs

Ensuring that biotechnology is seen as a U.S. national security priority.



State Government Affairs

Advancing state legislation and strengthening our relationship with the Council of State Bioscience Associations to move our industry forward.



Business Operations

Dedicated to convening the industry, growing membership, and providing the resources and infrastructure that enable the pursuit of BIO's mission.



Patient Advocacy and Alliance Development

Driving strategic engagement with patient advocacy organizations and coalitions, and enabling member patient advocacy efforts.



Legal

Trusted advisors and experienced counsel helping ensure compliance and governance.


Representing the Global Biotechnology Ecosystem By the numbers:

Membership breakdown



More than half of BIO's members are emerging small to mid-size biotech companies.

Global Representation







BIO International Convention is the premier convening for the biotechnology industry, with representatives across the industry, investors, service providers, government officials, regulators, and patient advocates. The BIO International Convention features programming across 18 different focus areas, including AI and digital health, next generation biotherapeutics, business development and more.

2025 Highlights

61K+ partnering meetings

Nearly **20,000** registrants from **68** countries

135+ sessions spanning **18** focus areas



Other BIO Events

As the largest global non-profit biotechnology trade association representing startups to Fortune 500 companies, BIO is proud to host a portfolio of partnering conferences that not only unite and empower biotech innovators and their ecosystem to improve lives, but also offer a broad and unbiased venue to seek investment and BD&L opportunities.

Upcoming Events

BIO-Patient Advocacy Changemakers Event

October 27-28, 2025..... Washington, DC

BIO-Europe

November 3-5, 2025 Vienna, Austria

IP Conference

November 17-19, 2025 Palm Springs, CA

BIO Partnering @ JPM Week

January 12-15, 2026 San Francisco, CA

BIO Investment & Growth Summit

March 2-3, 2026 Miami, FL

BIO Asia-Taiwan

July 15-19, 2026 Taipei, Taiwan

BIO 2026June 22-25, 2026
San Diego, CA

convention.bio.org

Policy Spotlight


The One, Big, Beautiful Bill Act (OBBBA), passed on July 3, corrects a key flaw in the Inflation Reduction Act by allowing orphan drugs that treat more than one rare disease to remain exempt from price controls.

"Biotechnology is at such a critical inflection point, and BIO is going to be the key catalyst that assures we can continue to grow the biotech industry and make it stronger than ever."

– Fritz Bittenbender, BIO Board Chair

Additionally, full R&D tax provisions under the OBBBA will allow small, emerging companies to be more nimble and more focused on getting innovative medicines from the lab bench to a patient's bedside.





Key policy priorities include:

Regulatory reform

Boldly and strategically modernize key regulations to ensure our regulatory processes match the speed and sophistication of scientific advances.

Strengthen domestic supply chains

Address the vulnerabilities in U.S. supply chains and advocating for the best ways to re-invigorate American biomanufacturing.

Enable capital formation

Ensure biotech innovators have the funds needed to support and grow their enterprise and advance science.

Protect core inventions and intellectual property

Strong IP laws not only protect investments - they also lead to more investments.

Shape the future with 21st Century Access

Address the financial and systemic barriers to patient access and availability of new innovations.

Advocate for vaccines

As a critical investment to protect and preserve public health.

Catalyst for Industry and Business Growth

As a non-profit organization, BIO invests member dues, BIO event fees, and use of the BIO Business Solutions programs back into BIO's industry advocacy efforts. This effectively doubles our ability to deliver benefits across the biotech ecosystem while:

Convening the global community:

The BIO International Convention is the largest life sciences event in the world, gathering more than 20,000 attendees every year to advance the business of biotech through knowledge-sharing, networking, and partnerships.

Members enjoy discounted registration rates.

Linking entrepreneurs:

Our dedicated partnering system connects BIO members with investors and industry collaborators to support business growth at nine events throughout the year. BIO facilitated more than 75,000 meetings in 2024.

Educating biotech professionals:

BIO provides on-demand access to more than 60 professional development courses and members receive discounted rates.

Unlocking value and savings:

BIO Business Solutions® is the largest cost savings program for the life sciences industry. Most members save more than their annual dues by participating in the BBS program.

Years helping member companies save money, time, and resources.

4,500+ Participating member companies.

Industry-leading partners across laboratory supply, insurance, travel, shipping.



Harnessing group purchasing power with BIO Business Solutions®

BIO Business Solutions® is the largest cost savings program for the life sciences industry. BIO negotiates volume-based discounts, favorable terms, and other benefits on products and services with industry leading suppliers on behalf of BIO members and the members of state and regional biotech associations.

By uniting the purchasing power of thousands of companies, BIO helps support the missions of its members - accelerating discoveries, reducing time to market, and enabling innovation at every stage of development.

BIO helps more than 4,500 companies save an aggregate of \$700 million every year.

BIO Business Solutions offers exclusive savings across a wide spectrum of lab and operational needs.

Laboratory & Research Supplies

From consumables to equipment, members access negotiated pricing on essentials that keep research moving forward.

Risk Management & Insurance

Comprehensive coverage and advisory services designed for the unique needs of life sciences organizations.

Business Operations & Corporate Services


Savings on travel, shipping, office supplies, and more to streamline day-to-day operations.

Specialized Services

Tailored solutions for human resources, compliance, and data security.

The Council of State Bioscience Associations

The Council of State Bioscience Associations (CSBA) is a coalition of independent state and territory based non-profit trade associations, each of which advocates for public policies that support responsible development and delivery of innovative life-sustaining and life-saving biotechnology solutions. Convened by BIO, CSBA's collective voice represents the true grassroots network of innovators, researchers, manufacturers and accelerators across the country.





Learn More

Visit bio.org/CSBA to learn more about CSBA, including the recent report, "The U.S. Bioscience Economy: Driving Economic Growth and Opportunity in States and Regions," which analyzes the sector's economic impact via employment, overall output and more.



The Industry's Storyteller

Storytelling is at the heart of BIO's priorities – sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. Helping to drive BIO's advocacy priorities are stories on the newest biotech advancements, perspectives from patients and caregivers on how biotech has affected their lives, and insights from industry leaders on their relentless pursuit to make the world a better place.

80%

Nearly 80% of BIO members rely on bio.news for critical advocacy updates.



Bio.News is a voice of life science and human health – driving BIO's core priorities with powerful storytelling and providing a platform for news and information about BIO members and the patients and stakeholders they serve.



